Qiagen N.V. (NASDAQ:QGEN) issued its quarterly earnings results on Thursday, July 27th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.02, MarketWatch Earnings reports. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The firm had revenue of $349 million for the quarter, compared to analyst estimates of $353.09 million. During the same period in the previous year, the firm earned $0.24 earnings per share. The company’s revenue was up 4.4% compared to the same quarter last year. Qiagen N.V. updated its FY17 guidance to $1.25-1.27 EPS.
Qiagen N.V. (QGEN) traded down 1.28% on Tuesday, hitting $31.68. The stock had a trading volume of 129,140 shares. The firm has a 50-day moving average of $33.97 and a 200 day moving average of $31.03. The company has a market capitalization of $7.23 billion, a price-to-earnings ratio of 96.88 and a beta of 1.14. Qiagen N.V. has a 52 week low of $24.86 and a 52 week high of $35.26.
QGEN has been the topic of several recent analyst reports. TheStreet lowered Qiagen N.V. from a “b-” rating to a “c” rating in a research note on Monday, April 24th. Commerzbank Ag reaffirmed a “buy” rating on shares of Qiagen N.V. in a research report on Monday, May 15th. Zacks Investment Research lowered Qiagen N.V. from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. BidaskClub raised Qiagen N.V. from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $31.00 target price (up from $28.00) on shares of Qiagen N.V. in a research report on Thursday, July 13th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Qiagen N.V. has a consensus rating of “Hold” and an average target price of $33.19.
ILLEGAL ACTIVITY NOTICE: “Qiagen N.V. (QGEN) Announces Quarterly Earnings Results” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.themarketsdaily.com/2017/08/08/qiagen-n-v-qgen-posts-quarterly-earnings-results-beats-estimates-by-0-02-eps-updated.html.
Hedge funds have recently modified their holdings of the company. Airain ltd purchased a new stake in shares of Qiagen N.V. during the second quarter valued at approximately $1,390,000. Prudential Financial Inc. raised its stake in shares of Qiagen N.V. by 9.8% in the second quarter. Prudential Financial Inc. now owns 7,841 shares of the company’s stock valued at $263,000 after buying an additional 700 shares during the last quarter. Great Lakes Advisors LLC purchased a new stake in shares of Qiagen N.V. during the second quarter valued at approximately $4,406,000. Marshall Wace North America L.P. purchased a new stake in shares of Qiagen N.V. during the second quarter valued at approximately $5,195,000. Finally, Frontier Capital Management Co. LLC raised its stake in shares of Qiagen N.V. by 3.6% in the second quarter. Frontier Capital Management Co. LLC now owns 2,536,075 shares of the company’s stock valued at $85,035,000 after buying an additional 87,069 shares during the last quarter. 59.84% of the stock is owned by institutional investors.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.